The Use of Kineret (Anakinra) in the Treatment of Familial Cold Urticaria
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
An open labelled trial of Kineret (anakinra) induction therapy (100mg./day) in over a four
week period in the treatment of Familial Cold Urticaria.
Familial Cold Urticaria (FCU) is a rare autosomal dominant condition manifesting symptoms
triggered by exposure to cold and variable in expression. Currently there is no standard
reliable agent available for the treatment of patients with FCU.This study will evaluate the
efficacy of Kineret (anakinra), an interleukin 1 receptor antagonist in induction and
maintenance therapy in patients with FCU.